AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01181973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegvisomant
Description: One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
Study NCT01181973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegvisomant
Description: Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
Study NCT02373865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin will be given in a daily dosage of 100 mg
Study NCT02373865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
Study NCT02373865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin-Placebo
Description: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
Study NCT02373865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride-Placebo
Description: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
Study NCT00617357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LTM (Strattice Reconstructive Tissue Matrix)
Description: Surgical mesh
Study NCT03792646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Exercise training + 20g whey protein
Study NCT03792646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Strength exercise
Study NCT03792646 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Description: Strength exercise
Study NCT00687908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Description: Topical Gel to the face, once daily in the evening for 24 weeks.
Study NCT00687908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Topical Gel to the face, once daily in the evening for 24 weeks.
Study NCT00006015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, \& 22)
Study NCT00006015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
Study NCT00006015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
Study NCT00006015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/sq m IV infusion over 2 hours Days 1 \& 15 of each cycle
Study NCT01445249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark guided ankle block.
Description: 25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
Study NCT01445249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNS guided block.
Description: This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
Study NCT02411240 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Air filtering
Description: The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
Study NCT02150941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioVac Direct Suction Device
Description: The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.
Study NCT02150941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endoscopy Suction
Description: Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
Study NCT03902769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prescribing conventional chemotherapy while with holding allo-SCT
Description: Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT
Study NCT03902769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prescribing conventional chemotherapy while with holding allo-SCT
Description: Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT
Study NCT03832283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD-MDD/CAT-DI screening via MyChart
Description: Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and >75=severe).
Study NCT03832283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD-MDD/CAT-DI screening during clinic visit
Description: During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and >75=severe).
Study NCT03832283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CAD-MDD/CAT-DI screening during clinic visit
Description: During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and >75=severe).
Study NCT03832283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAT-DI monitoring via MyChart
Description: Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (\<50) will indicate that a patient's MDD is in remission.
Study NCT03832283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHQ-9 monitoring during clinic visits
Description: During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score \< 5 will indicate that a patient's MDD is in remission.
Study NCT03832283 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PHQ-9 monitoring during clinic visits
Description: During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score \< 5 will indicate that a patient's MDD is in remission.
Study NCT02674139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T 380A IUD
Description: intrauterine contraceptive device T-shaped loaded with cupper
Study NCT02674139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T 380A IUD
Description: intrauterine contraceptive device T-shaped loaded with cupper
Study NCT01791985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547 / anastrozole or letrozole
Description: Patients will continue or restart the NSAI which they have progressed\* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~\*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment.
Study NCT00571623 — intervention group
Intervention type: OTHER
Intervention: Chest Physiotherapy
Description: 10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
Study NCT01927094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Comparison of probiotics vs. ORS
Study NCT01927094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ORS
Description: ORS ad libitum
Study NCT00499811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00499811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03598400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity interval training
Description: Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
Study NCT03598400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity continous training
Description: Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
Study NCT01937897 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bi-lateral massage
Description: Unilateral massage on the left side of the body.
Study NCT01937897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bi-lateral massage
Description: Unilateral massage on the left side of the body.
Study NCT01937897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bi-lateral massage
Description: Unilateral massage on the left side of the body.
Study NCT00372424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
Study NCT00372424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
Study NCT00372424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
Study NCT02358057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02358057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Study NCT04549181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase II: Problem-Solving for Rural HF Dyads
Description: Participants in the Intervention Group will be trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems collaboratively over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Dyadic problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this dyadic intervention is to move HF dyads toward a positive problem orientation and use of rational problem-solving strategies that support greater patient and family caregiver-contributed HF self-care.
Study NCT02204670 — intervention group
Intervention type: OTHER
Intervention: Acute release of irisin after a single exercise session.
Description: We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
Study NCT03053882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mouthwash
Description: mouthwash containing herbal peppermint or green tea
Study NCT00721409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg/d tablets orally on a continuous regimen
Study NCT01367275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: 800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
Study NCT01367275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2 by vein on Day 1 of a 14 day cycle.
Study NCT03405207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 50000 UNT Oral Capsule
Description: Holick's protocol of treating vitamin D deficiency lasting for 8 weeks
Study NCT02165813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide is a synthetic drug of the nitrothiazolide class. The main metabolite of NTZ is tizoxanide. The active ingredient is Nitazoxanide (2-acetyloxy-N(5-nitro-2-thiazolyl)benzamide), a synthetic agent for oral administration, at a concentration of 100 mg/5 ml.
Study NCT03825588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASAP (As Safe As Possible)
Description: ASAP (As Safe As Possible) is a brief intervention for adolescents hospitalized for suicide risk that focuses on the development of a safety plan, teaching emotion regulation and distress tolerance skills, along with 1-2 post-discharge follow-up calls to encourage adherence to use of the safety plan and to outpatient treatment.
Study NCT03825588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRITE smart phone app
Description: BRITE is a smart phone app that aims to support daily emotion regulation and a safety plan that is personalized to the needs and preferences of each adolescent.
Study NCT03825588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU (treatment as usual)
Description: TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.
Study NCT03825588 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU (treatment as usual)
Description: TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.
Study NCT02713178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine liposome injectable suspension
Description: bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
Study NCT02713178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline.
Study NCT01350817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + docetaxel
Description: docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
Study NCT01350817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel :75 mg/m² IV day 1 every 3 weeks.
Study NCT04288934 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collection and expansion of BM-MSC
Description: MSCs collection from patients owns marrow using a volume of 20 ml of bone marrow obtained from iliac crest of SCI patients under local anesthesia. Manipulations of blood and bone marrow are to be done according to Good Laboratory Practice (GLP) using the gradient sedimentation method.
Study NCT04288934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VI-SCI evaluation and patients' follow up
Description: * At 6, and 12 months post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline.~* The (ASIA)/(ISNCSCI) score will be repeated every 3 months to evaluate any motor or neurological changes~* The Spinal Cord Independence Measure (SCIM III) score will be repeated every 3 months to evaluate the effect on daily activities.~* Blood samples will be withdrawn from patients at 3 months interval for biomarkers detection.
Study NCT02165813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An oral suspension is supplied as a pink coloured powder formulation (sugar) that is reconstituted with 48 mL water prior to use to a final volume of 60 mls.
Study NCT02760875 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early weight bearing
Description: The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
Study NCT03405207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: identical as active drug providing by pharmaceutical company unless it is placebo
Study NCT00567203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3463275
Description: PF-3463275 10mg
Study NCT04041570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO S vaccine
Description: The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).
Study NCT04866966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared medical appointments for weight loss
Description: Shared medical appointments providing education and lifestyle change recommendations to promote weight loss in obese patients
Study NCT03640169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health management of TCM preventive medicine
Description: The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
Study NCT01180244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive cortical electrical stimulation
Description: Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
Study NCT01180244 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham treatment
Description: Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
Study NCT03150836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
Study NCT04190355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigant type
Description: The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on postoperative pain using different uniforms will be evaluated.
Study NCT04190355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5.25% NaOCl
Description: 5.25% NaOCl solution
Study NCT04190355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5.25% Cloraxid gel/ distilled water
Description: 5.25% Cloraxid gel/ distilled water
Study NCT00870454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 300 mg/d
Description: 75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder
Study NCT00870454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate 800 mg/d
Description: 200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3
Study NCT00870454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate 1,200 mg/d
Description: 200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3
Study NCT00870454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice daily
Study NCT00914407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 100% Oxygen inhalation for 30 minutes
Study NCT03150836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.